|Bid||114.00 x 36200|
|Ask||115.75 x 25000|
|Day's range||77.30 - 79.10|
|52-week range||59.00 - 82.20|
|PE ratio (TTM)||38.32|
|Earnings date||5 Sep 2018|
|Forward dividend & yield||0.34 (0.42%)|
|1y target est||66.08|
bioMérieux SA. (ENXTPA:BIM) trades with a trailing P/E of 40.5x, which is higher than the industry average of 27.8x. While this makes BIM appear like a stock to avoid orRead More...
SAINT-PRIEST, France, May 02, 2018 (GLOBE NEWSWIRE) -- Biom'up (EPA:BUP), a specialist in surgical hemostasis, today announced it has finalized the commercial infrastructure to support the imminent launch of its lead product HEMOBLAST Bellows. The Company has recruited senior management and a large number of independent specialist sales representatives to drive the nationwide marketing and sales campaign of HEMOBLAST Bellows, which is expected to start in mid-2018. With a large team of specialists now in place, and given its clinically demonstrated high value, we are confident that HEMOBLAST Bellows will make substantial inroads and become a fixture of hemostasis in operating rooms across the USA.
SAINT-PRIEST, France, April 16, 2018 (GLOBE NEWSWIRE) -- Biom'up (the "Company"), a specialist in surgical hemostasis, today announced its 2017 full-year results, as approved by the Company's Board of Directors on April 13, 2018. Etienne Binant, CEO of Biom'up, said: "2017 was a pivotal year for Biom'up, during which we successfully positioned the Company to become a strong contender in the hemostasis space.
Investors piled back into European stocks on Wednesday, boosting indexes higher in a rally a day after geopolitical concern caused a drop across equity markets. The pan-European STOXX 600 gained 0.7 percent, ...
Investors piled back into European stocks on Wednesday, boosting indexes higher in a relief rally after geopolitical concerns caused a sharp dip across equity markets. The pan-European STOXX 600 gained ...